[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2760886T3 - Immunocytokin-kombinationsterapi - Google Patents

Immunocytokin-kombinationsterapi Download PDF

Info

Publication number
DK2760886T3
DK2760886T3 DK12735490T DK12735490T DK2760886T3 DK 2760886 T3 DK2760886 T3 DK 2760886T3 DK 12735490 T DK12735490 T DK 12735490T DK 12735490 T DK12735490 T DK 12735490T DK 2760886 T3 DK2760886 T3 DK 2760886T3
Authority
DK
Denmark
Prior art keywords
immunocytokin
combination therapy
therapy
combination
immunocytokin combination
Prior art date
Application number
DK12735490T
Other languages
English (en)
Inventor
Kathrin Schwager
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Application granted granted Critical
Publication of DK2760886T3 publication Critical patent/DK2760886T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK12735490T 2011-09-26 2012-06-29 Immunocytokin-kombinationsterapi DK2760886T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539131P 2011-09-26 2011-09-26
PCT/EP2012/062705 WO2013045125A1 (en) 2011-09-26 2012-06-29 Immunocytokine combination therapy

Publications (1)

Publication Number Publication Date
DK2760886T3 true DK2760886T3 (da) 2019-12-09

Family

ID=46514324

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12735490T DK2760886T3 (da) 2011-09-26 2012-06-29 Immunocytokin-kombinationsterapi

Country Status (9)

Country Link
US (1) US10195253B2 (da)
EP (1) EP2760886B1 (da)
AU (1) AU2012314860B2 (da)
CA (1) CA2849033C (da)
DK (1) DK2760886T3 (da)
ES (1) ES2762179T3 (da)
RU (1) RU2628089C2 (da)
WO (1) WO2013045125A1 (da)
ZA (1) ZA201401952B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2988784A1 (en) 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
GB201419184D0 (en) 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins
BR112018008326A2 (pt) 2015-10-30 2018-10-30 Aleta Biotherapeutics Inc. composições e métodos para o tratamento de câncer
EP3368077A4 (en) 2015-10-30 2019-10-16 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS OF TUMOR TRANSDUCTION
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
RU2758139C2 (ru) * 2016-11-09 2021-10-26 Филоджен С.П.А. Иммуноконъюгаты il2 и мутантного tnf
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
PE20200303A1 (es) 2017-05-24 2020-02-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
AU2023240296A1 (en) 2022-03-21 2024-11-07 Philogen S.P.A TNFα IMMUNOCONJUGATE PREPARATION
AU2023237604A1 (en) 2022-03-23 2024-11-07 Philogen S.P.A Il2 immunoconjuqate preparation
CN115154505A (zh) * 2022-07-20 2022-10-11 上海市中西医结合医院 香连丸在制备用于免疫治疗泛癌患者减毒增效的药物中的应用
WO2024047237A1 (en) 2022-09-01 2024-03-07 Philogen S.P.A. Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US8623373B2 (en) 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
FR2805766B1 (fr) 2000-03-06 2002-05-24 Air Liquide Torche double-flux pour soudage a l'arc
KR101281208B1 (ko) * 2005-05-11 2013-07-26 필로겐 에스.피.에이. 피브로넥틴 ed-b에 대한 항체 l19 및 인터루킨12의 융합 단백질
AU2010285071A1 (en) * 2009-08-17 2012-02-02 Roche Glycart Ag Targeted immunoconjugates
US20110300186A1 (en) * 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies

Also Published As

Publication number Publication date
WO2013045125A1 (en) 2013-04-04
RU2014107983A (ru) 2015-11-10
EP2760886B1 (en) 2019-10-02
ES2762179T3 (es) 2020-05-22
AU2012314860A1 (en) 2014-05-15
CA2849033A1 (en) 2013-04-04
US20140219920A1 (en) 2014-08-07
AU2012314860B2 (en) 2017-02-23
WO2013045125A8 (en) 2019-05-16
US10195253B2 (en) 2019-02-05
ZA201401952B (en) 2015-02-25
CA2849033C (en) 2020-05-05
EP2760886A1 (en) 2014-08-06
RU2628089C2 (ru) 2017-08-14
NZ624082A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
BR112013033974A2 (pt) terapia de combinação
DK2760886T3 (da) Immunocytokin-kombinationsterapi
DK2769050T3 (da) Propsensor
FI20115876A0 (fi) Yhdistelmähoito
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
DE102011100082A8 (de) Traygreifvorrichtung
CO6960543A2 (es) 2-tiopirimidinonas
CO6970601A2 (es) Nueva combinación
DK3141251T3 (da) Koloskopi - forberedelse
BR112014000742A2 (pt) terapia de combinação de als
CO6880064A2 (es) Métodos terapéuticos
DE112011104936A5 (de) Stanzstauchniet
FI20115640A0 (fi) Yhdistelmähoito
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DK2694056T3 (da) Terapeutisk behandling
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
DE102011117169A8 (de) Absetzplattenanordnung
DE112011105396A5 (de) Nachverfestigungsverfahren